The combination of nab-sirolimus (Fyarro) and letrozole elicited responses with acceptable safety in patients with advanced or recurrent endometrioid endometrial cancer, according to findings from an interim analysis of the phase 2 ECC-201 study…
Nab-Sirolimus Plus Letrozole Shows Early Activity in Advanced/Recurrent Endometrioid Endometrial Cancer
